| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |